NCT05401786 2026-03-12
RAD-IO
The Netherlands Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT05882734 2026-02-17
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
EMD Serono
Phase 1/2 Active not recruiting
NCT05553834 2026-01-23
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
Duke University
Phase 2 Active not recruiting
NCT05785767 2026-01-22
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT05800015 2026-01-22
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT06161441 2026-01-12
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT05704634 2025-10-27
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06269133 2025-08-27
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Regeneron Pharmaceuticals
Active not recruiting
NCT03916627 2025-04-11
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
Phase 2 Active not recruiting